二至丸联合甲氨蝶呤经Wnt1/LRP5/β-catenin通路协同调节胶原诱导性关节炎大鼠成骨细胞
本研究结合网络药理学预测与动物及细胞实验,探讨二至丸联合甲氨蝶呤对类风湿关节炎的协同作用及机制。网络药理学显示Wnt/β-catenin通路为两药与RA共同关联的首要通路;体内实验表明联合治疗减轻关节炎严重程度与踝骨损伤,升高BALP、降低TRACP血清水平,并调控踝部Wnt1、LRP5、β-catenin、Runx2、BALP、BGP的mRNA表达;体外实验显示联合处理改善成骨细胞Wnt1/LRP5/β-catenin通路相关基因表达。结论提示二至丸联合甲氨蝶呤通过调控该通路协同调节RA成骨细胞。
要点
- 二至丸联合甲氨蝶呤可减轻胶原诱导性关节炎大鼠关节炎严重程度与踝骨损伤。
- 联合治疗升高血清BALP、降低TRACP,并调控踝部Wnt1/LRP5/β-catenin通路及成骨相关基因mRNA表达。
- 网络药理学提示Wnt/β-catenin信号通路为二至丸、甲氨蝶呤与RA共享的首要通路。
核心结论
- 二至丸联合甲氨蝶呤对RA大鼠成骨细胞发挥协同调节作用,与调控Wnt1/LRP5/β-catenin信号通路相关。
研究设计与样本
- 研究采用网络药理学预测结合体内外实验验证:在胶原诱导性关节炎大鼠中比较甲氨蝶呤单药、二至丸单药及联合治疗,并以处理大鼠血清干预大鼠成骨样UMR-106细胞系。
主要发现
- 网络药理学分析显示Wnt/β-catenin信号通路是甲氨蝶呤、二至丸与RA共享的首要信号通路。
- 体内实验显示二至丸联合甲氨蝶呤减轻关节炎严重程度、缓解踝骨损伤,升高BALP并降低TRACP血清水平。
- 体内实验显示联合治疗调控踝部Wnt1、LRP5、β-catenin、Runx2、BALP、BGP的mRNA表达。
- 体外实验显示二至丸联合甲氨蝶呤可改善成骨细胞Wnt1/LRP5/β-catenin通路相关基因表达。
临床怎么用
- 对RA合并骨代谢异常者,可考虑二至丸与甲氨蝶呤联用以协同调节成骨细胞,但需结合临床辨证与监测。
局限性
- 研究为动物与细胞实验及网络药理学预测,尚未提供人体临床证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized by chronic synovitis, bone erosion, and bone loss. Erzhi Pill (EZP), a classic Chinese patent medicine, is often used to treat osteoporosis and shows a capacity for bone metabolism regulation. Methotrexate (MTX), an essential drug for RA treatment, has been reported to inhibit generalized bone loss in RA patients. However, the combined therapeutic effects and mechanism of EZP and MTX in RA have not been fully elucidated. The aim of this study was to investigate the synergistic effect of EZP and MTX on RA and to explore the underlying mechanism through network pharmacological prediction and experimental verification. Chemical compounds of EZP, human target proteins of EZP and MTX, and RA-related human genes were identified in the Encyclopedia of Traditional Chinese Medicine database, PubChem database, and NCBI database, respectively. The molecular network of EZP and MTX in RA was generated and analyzed with Ingenuity Pathway Analysis software according to the datasets. Then, MTX monotherapy, EZP monotherapy, and combined MTX and EZP therapy were administered to collagen-induced arthritis rats, followed by assessment of pathological score, bone damage, bone alkaline phosphatases (BALP), and tartrate-resistant acid phosphatase (TRACP), and of gene levels related to the Wnt1/LRP5/β-catenin pathway according to network pharmacological analysis. Finally, serum samples from MTX-, EZP- and MTX+EZP-treated rats were used to treat the rat osteoblast (OB)-like UMR-106 cell line to evaluate gene levels related to Wnt1/LRP5/β-catenin. Network pharmacological analysis showed that the Wnt/β-catenin signaling pathway was the top signaling pathway shared among MTX, EZP, and RA. The results from in vivo experiments indicated that EZP combined with MTX reduced arthritis severity, alleviated ankle bone damage, increased BALP and decreased TRACP serum levels, and regulated the mRNA expression of Wnt1, LRP5, β-catenin, Runx2, BALP, and BGP in the ankles. In vitro experiments showed that EZP combined with MTX could also improve the expression of genes related to the Wnt1/LRP5/β-catenin pathway. This study demonstrated that EZP in combination with MTX played a synergistic role in regulating OBs in RA, which was connected to the modulatory effect of EZP and MTX on the Wnt1/LRP5/β-catenin signaling pathway.
引用
- Li X, Lu X, Fan D, et al. Synergistic Effects of Erzhi Pill Combined With Methotrexate on Osteoblasts Mediated via the Wnt1/LRP5/β-Catenin Signaling Pathway in Collagen-Induced Arthritis Rats. Front Pharmacol. 2020. PMID: 32218732. doi:10.3389/fphar.2020.00228
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。